Skip to nav Skip to content

Clinical Trial Search

290 Clinical Trials Found

Clinical Trial 21143

Disease Site: Mycosis Fungoides
PI: Sokol, Lubomir

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan

Clinical Trial 21122

A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AZD0486, a Bispecific Antibody Targeting CD19 in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 20641

A Randomized Pilot Trial of Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib and Binimetinib in Advanced Melanoma
Disease Site: Melanoma, skin
PI: Eroglu, Zeynep

Clinical Trial 19319

InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Disease Site: Penis / penile cancer, Other Male Genital
PI: Spiess, Philippe

Clinical Trial 20056

Phase II Clinical Trial of Green Tea Catechins in Men on Active Surveillance (AS)
Disease Site: Prostate
PI: Kumar, Nagi

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 22080

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma
Disease Site: Non-Hodgkin's Lymphoma
PI: Chavez, Julio

Clinical Trial 21056

Disease Site: Lymphoid Leukemia
PI: Sandoval-Sus, Jose

Clinical Trial 21634

A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas
Disease Site: Non-Hodgkin's Lymphoma
PI: Bello, Celeste

Clinical Trial 20938

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm
Disease Site: Lung
PI: Chiappori, Alberto